摘要
目的:探讨细针吸取细胞学(fine needle aspiration cytology,FNAC)结合LunX mRNA定量检测在诊断肺癌淋巴结转移中的应用价值。方法:选择46例肺癌患者进行研究,其中鳞癌22例,腺癌17例,小细胞癌4例,低分化癌不能明确类型3例;同期20例非肺癌患者为对照组。利用细针吸取细胞学穿刺取材,结合细胞学和应用逆转录PCR定量检测穿刺样本LunX mRNA表达水平,确定肺癌患者是否存在淋巴结转移。结果:肺癌组穿刺标本中LunXmRNA表达的阳性率为84.8%,对照组穿刺标本的阳性率仅为5%,两组阳性率具有显著性差异(X^2=37.16,P<0.01),并且肺癌转移组与对照组相比较,LunX mRNA平均拷贝数具有显著性差异(Z=-5.807,P<0.01)。肺癌淋巴结转移患者中LunX mRNA表达的阳性率分别为转移性鳞癌86.4%(19/22)、腺癌70.6%(12/17)、小细胞癌75.0%(3/4)、低分化癌66.7%(2/3),各组间无显著性差异(P=0.482),且各组间LunX mRNA平均拷贝数亦无显著性差异(F=0.377,P=0.770)。结论:细针吸取细胞学联合LunX mRNA定量检测判断肺癌淋巴结转移是一种微创、快速、准确的手段,有较高的敏感性和特异性。
Objective: This work investigates the diagnostic significance of fine needle aspiration cytology ( FNAC ) and LunX mRNA for lymph node metastasis in lung cancer. Methods: FNAC was used to examine the lymph nodes of lung cancer patients; quan- titative real-time reverse transcription polymerase chain reaction ( RT - PCR ) was employed to determine the LunX mRNA levels in the biopsy materials. Both these methods could detect whether lymph node metastasis occurred among lung cancer patients. Results: In examining the lymph nodes, LunX mRNA was detected in 84.8% of the patients with lung cancer, whereas only in 5 % patients in the control group ( X^2 = 37.16, P 〈 0.01 ). LunX mRNA copies in the group with metastatic lung cancer were significantly different with the control group ( Z = - 5.807, P 〈 0.01 ). Furthermore, the positive rates for LunX mRNA in different histologic types were as follows: 86.3 % ( 19 / 22 ) in metastatic squamous cell carcinoma, 70.6 % ( 12 / 17 ) in adenocarcinoma, 75 % ( 3 / 4 ) in small cell carcinoma, and 66.7 % ( 2 / 3 ) in poorly differentiated carcinoma. No significant difference was observed in the statistical data ( P = 0.482 ) and LunX mRNA copy numbers ( F - 0.377, P = 0.770 ) of these groups. Conclusion: FNAC combined with the detection of LunX mRNA levels is a minimally invasive, rapid, and accurate diagnostic method for diagnosing lymph node metastasis in lung cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2012年第12期864-867,共4页
Chinese Journal of Clinical Oncology